THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Amendment #4 to Clinical...Clinical Services Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Change Order 4 (“Change Order”) to the Clinical Services Agreement signed 15 June 2011 (“Clinical Services Agreement”), is by and among:
THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Clinical Trials Global Master...Clinical Trials Global Master Services Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations • England
THIS CLINICAL TRIALS GLOBAL MASTER SERVICES AGREEMENT (“the Agreement”) is made effective as of the date of the last signature by the parties’ authorized representatives (the “Effective Date”) by and between Quest Diagnostics Clinical Laboratories, Inc. (“Quest Diagnostics”), with a principal office located at 1201 South Collegeville Road, Collegeville, PA 19426-2998 USA and RedHill Biopharma, Ltd., with a principal office located at 21 Haarba’a St., Tel-Aviv 64739, Israel (“Client”). Quest Diagnostics and Client shall each herein be referred to as a “Party” and together as the “Parties”.
THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT TO ASSET PURCHASE...Asset Purchase Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment to Asset Purchase Agreement (this “Amendment”) is made as of 27 February 2014 (the “Amendment Effective Date”), by and among RedHill Biopharma Ltd., an Israeli company having its principal place of business at 21 Ha’arba’a Street, Tel-Aviv 64739, Israel (“RedHill”), and Giaconda Limited ACN 108 088 517, an Australian public limited company having its registered office at Ground Floor, 44 East Street, Five Dock, NSW 2046, Australia (“Giaconda”). Each of RedHill and Giaconda is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
Service Agreement – A Formulation development of RHB-105 in oral solid dosage form and manufacture of clinical supplies Amendment 3Service Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
STRICTLY CONFIDENTIALConfidentiality Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New York
This Agreement (the “Agreement”) is made and entered into to be effective as of 27 February 2014 (the “Effective Date”) by and between RedHill Biopharma Ltd., an Israeli company (“RedHill”), and Salix Pharmaceuticals, Inc., a California corporation (“Salix”). RedHill and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CLINICAL TRIALS GLOBAL MASTER SERVICES AGREEMENT AMENDMENT NO. 1Clinical Trials Global Master Services Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No. 1 is made effective as of the date last signed below ("Amendment No. 1 Effective Date") by and between RedHill Biopharma, Ltd. ("Client") and Quest Diagnostics Clinical Laboratories, Inc. ("Quest Diagnostics"). This Amendment No. 1 amends the Clinical Trials Global Master Services Agreement dated 27-December-2012 to which both Client and Quest Diagnostics are parties (the "Agreemenf').
Service Agreement – A Formulation development of RHB-105 in oral solid dosage form and manufacture of clinical suppliesService Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. MASTER SERVICES AGREEMENTMaster Services Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations • England
This Master Services Agreement (“Agreement”) is entered into effective as __________ __, 2012 by Clinipace, Inc. (“Clinipace”) a Delaware Corporation located at 3800 Paramount Parkway Suite 100 Morrisville, NC 27560 and RedHill Biopharma LTD (“REDHILL”) a pharmaceutical company with offices at 21 Ha’arba’a St. Tel Aviv 64739, Israel.
THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Project Order # 1879 RHB-104...Manufacturing Amendment • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
THIS PROJECT ORDER No. 1879 RHB-104 Manufacturing Amendment 1 is between RedHill Biopharma Ltd. (“SPONSOR”) and 7810962 Canada Inc. (“MANAGER”) and, upon execution by both parties, shall be incorporated into the Service Agreement signed on 5July2014 between SPONSOR and MANAGER.
THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Master Service Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This letter is to confirm that 7810962 Canada Inc agree to extend our undertakings and obligations to the development of RHB-105. The extension of our obligations does not oblige 7810962 Canada Inc. to perform particular studies or services for the development of RHB-105 and any studies or services that we perform for Redhill Biopharma Ltd will be following our written approval.
Amendment 3 to Clinical Services Agreement Sponsor’s study drug RHB-104Clinical Services Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment 3 (“Change Order”) to the Clinical Services Agreement signed 15 June 2011 (“Clinical Services Agreement”), is by and among:
THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Service Agreement - Y...Service Agreement • February 26th, 2015 • RedHill Biopharma Ltd. • Pharmaceutical preparations
